Tabs: Avoid concomitant strong CYP3A inhibitors or P-gp inhibitors. Concomitant with moderate CYP3A inhibitors or P-gp inhibitors; monitor. Concomitant with sensitive CYP3A substrates (eg ...

Journavx is approved for all types of moderate-to-severe acute pain and ... The FDA warns that Journavx should not be taken with strong CYP3A inhibitors or grapefruit products due to potential ...

Because this enzyme is regarded as the acid (proton) pump within the parietal cell, vonoprazan has been characterized as a type of gastric proton-pump inhibitor, in that it blocks the final step ...